Literature DB >> 12920303

Predominant autoantibody production by early human B cell precursors.

Hedda Wardemann1, Sergey Yurasov, Anne Schaefer, James W Young, Eric Meffre, Michel C Nussenzweig.   

Abstract

During B lymphocyte development, antibodies are assembled by random gene segment reassortment to produce a vast number of specificities. A potential disadvantage of this process is that some of the antibodies produced are self-reactive. We determined the prevalence of self-reactive antibody formation and its regulation in human B cells. A majority (55 to 75%) of all antibodies expressed by early immature B cells displayed self-reactivity, including polyreactive and anti-nuclear specificities. Most of these autoantibodies were removed from the population at two discrete checkpoints during B cell development. Inefficient checkpoint regulation would lead to substantial increases in circulating autoantibodies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12920303     DOI: 10.1126/science.1086907

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  879 in total

1.  Arginine mutations in antibody complementarity-determining regions display context-dependent affinity/specificity trade-offs.

Authors:  Kathryn E Tiller; Lijuan Li; Sandeep Kumar; Mark C Julian; Shekhar Garde; Peter M Tessier
Journal:  J Biol Chem       Date:  2017-08-04       Impact factor: 5.157

2.  TRAF3 Acts as a Checkpoint of B Cell Receptor Signaling to Control Antibody Class Switch Recombination and Anergy.

Authors:  Zhangguo Chen; Alexandra Krinsky; Rachel A Woolaver; Xiaoguang Wang; Samantha M Y Chen; Vince Popolizio; Ping Xie; Jing H Wang
Journal:  J Immunol       Date:  2020-06-26       Impact factor: 5.422

3.  Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell anergy.

Authors:  Shannon K O'Neill; Andrew Getahun; Stephen B Gauld; Kevin T Merrell; Idan Tamir; Mia J Smith; Joseph M Dal Porto; Quan-Zhen Li; John C Cambier
Journal:  Immunity       Date:  2011-11-09       Impact factor: 31.745

4.  Induction of antigen-specific tolerance to bone marrow allografts with CD4+CD25+ T lymphocytes.

Authors:  Olivier Joffre; Nathalie Gorsse; Paola Romagnoli; Denis Hudrisier; Joost P M van Meerwijk
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

Review 5.  Immunological tolerance as a barrier to protective HIV humoral immunity.

Authors:  Kristin Ms Schroeder; Amanda Agazio; Raul M Torres
Journal:  Curr Opin Immunol       Date:  2017-07-17       Impact factor: 7.486

6.  Transitional B cells exhibit a B cell receptor-specific nuclear defect in gene transcription.

Authors:  Sarah F Andrews; David J Rawlings
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

7.  Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production.

Authors:  Elizabeth Cotzomi; Panos Stathopoulos; Casey S Lee; Alanna M Ritchie; John N Soltys; Fabien R Delmotte; Tyler Oe; Joel Sng; Ruoyi Jiang; Anthony K Ma; Jason A Vander Heiden; Steven H Kleinstein; Michael Levy; Jeffrey L Bennett; Eric Meffre; Kevin C O'Connor
Journal:  Brain       Date:  2019-06-01       Impact factor: 13.501

8.  Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning.

Authors:  Thomas Tiller; Eric Meffre; Sergey Yurasov; Makoto Tsuiji; Michel C Nussenzweig; Hedda Wardemann
Journal:  J Immunol Methods       Date:  2007-10-31       Impact factor: 2.303

9.  A role for IRF8 in B cell anergy.

Authors:  Simanta Pathak; Shibin Ma; Vipul Shukla; Runqing Lu
Journal:  J Immunol       Date:  2013-11-11       Impact factor: 5.422

10.  Chronic lymphocytic leukemia monitoring with a Lamprey idiotope-specific antibody.

Authors:  Hirotomo Nakahara; Brantley R Herrin; Matthew N Alder; Rosa Catera; Xiao-Jie Yan; Nicholas Chiorazzi; Max D Cooper
Journal:  Cancer Immunol Res       Date:  2013-10       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.